Skip to main content

Table 1 Synergy indices for combinations of latency reversing agents

From: HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells

 

No RAL

+RAL

Bryostatin

 +TSA

1.06 ± 0.13

1.49 ± 0.28

 +SAHA

0.94 ± 0.07

1.09 ± 0.05

 +Scriptaid

0.95 ± 0.05

1.19 ± 0.09

 +JQ1

0.85 ± 0.06

1.14 ± 0.10

 +HMBA

0.92 ± 0.13

1.12 ± 0.16

 +Disulfiram

0.83 ± 0.06

0.79 ± 0.03

Prostratin

 +TSA

1.02 ± 0.04

1.44 ± 0.14

 +SAHA

0.96 ± 0.08

1.30 ± 0.19

 +Scriptaid

0.97 ± 0.05

1.42 ± 0.18

 +JQ1

0.87 ± 0.07

1.19 ± 0.16

 +HMBA

0.63 ± 0.10

0.77 ± 0.29

 +Disulfiram

0.55 ± 0.14

0.68 ± 0.14

JQ1

  

 +TSA

0.72 ± 0.08

0.88 ± 0.22

 +SAHA

0.87 ± 0.11

0.90 ± 0.11

 +Scriptaid

0.84 ± 0.15

0.90 ± 0.10

HMBA

 +TSA

0.63 ± 0.17

0.78 ± 0.03

 +SAHA

0.62 ± 0.21

0.81 ± 0.11

 +Scriptaid

0.69 ± 0.14

0.91 ± 0.14

Disulfiram

 +TSA

0.68 ± 0.11

0.72 ± 0.13

 +SAHA

0.63 ± 0.06

0.69 ± 0.06

 +Scriptaid

0.85 ± 0.17

0.98 ± 0.19

  1. Synergy indices were calculated from 3 independent experiments with different cell donors, based on the number of GFP+ cells. Synergy was calculated according to [95] and synergy indices significantly >1 are indicated in italicized text. Additional file 1: Figure S5 contributes data for one of the 3 experiments